New

AI v2.0 Beta Launched. Experience the future of pharmaceutical care.

Try Now
Drug info language
Switches all medical info on this page (labels, indications, leaflet) without changing the rest of the interface.
Highly Regulated (List I)Translated

ONDAPHREN

8 MG/Orodispersible Tablet/ONDANSERTON
EL KENDI DU MEDICAMENT
ManufacturerVerified lab

EL KENDI DU MEDICAMENT

Public retail price
N/ADZD
Reference price (TR): 800.00 DZD

Identification

Active ingredient (INN)
ONDANSERTON
Internal code
05 K 155
Country of Origin
Algeria
Pharmaceutical form
Orodispersible Tablet
Prescription List
Highly Regulated (List I)
Packaging
b/04
ONDAPHREN
Clinical View
Highly Regulated (List I)

DAWA Clinical Workbench v2.0

Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.

Associated Conditions

Lactation QT space extension Amygdalectomy and adenoidectomy Child between and 18 years Female likely to be pregnant Pregnancy, last 6 months (of) Congestive heart failure Moderate to severe hepatic impairment Newborn exposed in utero to the medicine Intestinal obstruction Subject at risk of QT space prolongation.

Mechanism of Action

Mechanism of action

Ondansetron is a potent and highly selective antagonist of serotonin 5-HT3 receptors involved in emetic reflex phenomena.

Its precise mode of action allowing control of nausea and vomiting is not known.

Chemotherapy and radiotherapy can lead to 5-HT release into the small intestine triggering a vomiting reflex by stimulation of 5-HT3 receptors located on the afferent fibres of the wave.

Ondansetron blocks the initiation of this reflex.

The afferent fibres of the wave can also cause 5-HT release into the postrema area, located in the floor of the fourth ventricle and this can also promote vomiting through a central mechanism.

The effect of ondansetron in the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy can also cause 5-HT release in the postrema area, located in the floor of the fourth ventricle and this can also promote vomiting through a central mechanism.

The effect of ondansetron in the management of nausea and vomiting induced by cytotoxic chemotherapy and radiation therapy is probably due to an antagonism of the 5-HT3 receptors on both central and peripheral nervous system.

Adverse Effects

  • Liver status (abnormality) (Uncommon)
  • Dermatosis (Very rare)
  • Lyell's syndrome Toxic epidermal necrolysis
  • Stevens-Johnson Syndrome Chest pain (Uncommon)
  • Immediate hypersensitivity (Rare)
  • Anaphylactic reaction Vision disorder (Rare)
  • Transitional blindness (Very rare)
  • Cortical blindness
  • Feeling dizzy (Rare)
  • Vertigo (Rare)
  • Arrhythmia (Uncommon)
  • Hot flash (Common)
  • Congestive puff (Common)
  • Bradycardia (Uncommon)
  • Hypotension (Uncommon)
  • QT space extension (Rare)
  • Torsades de pointes
  • Myocardial Ischemia ST segment abnormal with electrocardiogram ST-T segment anomaly
  • Hoquet (Uncommon)
  • Constipation (Common)
  • Sensation of anal burn Ileus Intestinal occlusion
  • Headache (Very common)
  • Convulsions (Uncommon)
  • Extrapyramidal syndrome (Uncommon)
  • Abnormal movement (Uncommon)
  • Oculogy crisis Dyskinesia Dystonia.

Alternatives